TipRanks
Agilent (CH:AG8)
:AG8
Switzerland Market
AG8
Agilent
RESEARCH TOOLSreports

Agilent (AG8) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AG8 Analyst Ratings

Strong Buy
14Ratings
Strong Buy
11 Buy
3 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Agilent
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AG8 Stock 12 Month Forecast

Average Price Target

―
Based on 14 Wall Street analysts offering 12 month price targets for Agilent in the last 3 months. The average price target is CHF148.21 with a high forecast of CHF158.46 and a low forecast of CHF125.10. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"116":"CHF116","159":"CHF159","126.75":"CHF126.8","137.5":"CHF137.5","148.25":"CHF148.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":158.4608949,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF158.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148.21455131999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF148.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125.1007065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF125.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[116,126.75,137.5,148.25,159],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.557,120.70345345384615,123.84990690769231,126.99636036153846,130.1428138153846,133.28926726923078,136.43572072307694,139.58217417692308,142.72862763076924,145.87508108461537,149.02153453846154,152.1679879923077,155.31444144615386,{"y":158.4608949,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.557,119.91527317846153,122.27354635692308,124.63181953538461,126.99009271384614,129.34836589230767,131.70663907076923,134.06491224923076,136.4231854276923,138.78145860615382,141.13973178461535,143.49800496307688,145.85627814153844,{"y":148.21455131999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.557,118.13728511538461,118.71757023076923,119.29785534615385,119.87814046153846,120.45842557692308,121.03871069230769,121.61899580769231,122.19928092307693,122.77956603846154,123.35985115384615,123.94013626923078,124.52042138461539,{"y":125.1007065,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":117.557,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.557,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF158.46Average Price TargetCHF148.21Lowest Price TargetCHF125.10
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:AG8
Michael Ryskin
Bank of America Securities
Bank of America Securities
CHF150.12
Buy
―
Reiterated
09/28/26
Agilent Maintained at Buy as Autonomous Lab Opportunity and China Strategy Support Steady $180 Price Target
Bernstein Analyst forecast on CH:AG8
Eve Burstein
Bernstein
Bernstein
CHF150.12
Buy
―
Reiterated
09/25/26
Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN)
Goldman Sachs Analyst forecast on CH:AG8
Evie Koslosky
Goldman Sachs
Goldman Sachs
CHF145.95→CHF154.29
Buy
―
Reiterated
09/20/26
Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Ascendis Pharma (ASND)
Jefferies Analyst forecast on CH:AG8
John Dunigan
Jefferies
Jefferies
CHF150.95
Hold
―
Reiterated
09/17/26
Analysts Conflicted on These Healthcare Names: Agilent (NYSE: A) and Aquestive Therapeutics (NASDAQ: AQST)
UBS Analyst forecast on CH:AG8
Unknown Analyst
UBS
Not Ranked
UBS
CHF137.61
Hold
―
Initiated
09/08/26
Agilent (A) Initiated with a Hold at UBS
Morgan Stanley Analyst forecast on CH:AG8
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
CHF145.95
Buy
―
Reiterated
09/01/26
Morgan Stanley Sticks to Its Buy Rating for Agilent (A)
Stifel Nicolaus Analyst forecast on CH:AG8
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
CHF150.12
Buy
―
Reiterated
08/30/26
Stifel Nicolaus Reaffirms Their Buy Rating on Agilent (A)
TD Cowen Analyst forecast on CH:AG8
Daniel Brennan
TD Cowen
TD Cowen
CHF129.27→CHF150.12
Buy
―
Assigned
08/27/26
Agilent Price Target Raised to $180 as Broad-Based Outperformance Drives Attractive Risk-Reward, Says Brennan
Piper Sandler Analyst forecast on CH:AG8
David Westenberg
Piper Sandler
Piper Sandler
CHF125.1
Hold
―
Reiterated
08/27/26
Piper Sandler Sticks to Its Hold Rating for Agilent (A)
Barclays Analyst forecast on CH:AG8
Luke Sergott
Barclays
Barclays
CHF125.1→CHF145.95
Buy
―
Reiterated
08/27/26
Agilent price target raised to $175 from $150 at BarclaysAgilent price target raised to $175 from $150 at Barclays
J.P. Morgan Analyst forecast on CH:AG8
Casey Woodring
J.P. Morgan
J.P. Morgan
CHF150.12→CHF158.46
Buy
―
Reiterated
08/27/26
Agilent price target raised to $190 from $180 at JPMorganAgilent price target raised to $190 from $180 at JPMorgan
Evercore ISI Analyst forecast on CH:AG8
Vijay Kumar
Evercore ISI
Evercore ISI
CHF123.43→CHF143.45
Buy
―
Reiterated
08/27/26
Agilent price target raised to $172 from $148 at Evercore ISIAgilent price target raised to $172 from $148 at Evercore ISI
Citi Analyst forecast on CH:AG8
Patrick B Donnelly
Citi
Citi
CHF154.29→CHF158.46
Buy
―
Reiterated
08/27/26
Agilent price target raised to $190 from $185 at CitiAgilent price target raised to $190 from $185 at Citi
RBC Capital Analyst forecast on CH:AG8
Dan Leonard
RBC Capital
RBC Capital
CHF129.27→CHF154.29
Buy
―
Reiterated
08/26/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
HSBC Analyst forecast on CH:AG8
Sidharth Sahoo
HSBC
HSBC
CHF150.12→CHF137.61
Buy
―
Reiterated
06/03/26
Agilent price target lowered to $165 from $180 at HSBCAgilent price target lowered to $165 from $180 at HSBC
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:AG8
Michael Ryskin
Bank of America Securities
Bank of America Securities
CHF150.12
Buy
―
Reiterated
09/28/26
Agilent Maintained at Buy as Autonomous Lab Opportunity and China Strategy Support Steady $180 Price Target
Bernstein Analyst forecast on CH:AG8
Eve Burstein
Bernstein
Bernstein
CHF150.12
Buy
―
Reiterated
09/25/26
Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN)
Goldman Sachs Analyst forecast on CH:AG8
Evie Koslosky
Goldman Sachs
Goldman Sachs
CHF145.95→CHF154.29
Buy
―
Reiterated
09/20/26
Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Ascendis Pharma (ASND)
Jefferies Analyst forecast on CH:AG8
John Dunigan
Jefferies
Jefferies
CHF150.95
Hold
―
Reiterated
09/17/26
Analysts Conflicted on These Healthcare Names: Agilent (NYSE: A) and Aquestive Therapeutics (NASDAQ: AQST)
UBS Analyst forecast on CH:AG8
Unknown Analyst
UBS
Not Ranked
UBS
CHF137.61
Hold
―
Initiated
09/08/26
Agilent (A) Initiated with a Hold at UBS
Morgan Stanley Analyst forecast on CH:AG8
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
CHF145.95
Buy
―
Reiterated
09/01/26
Morgan Stanley Sticks to Its Buy Rating for Agilent (A)
Stifel Nicolaus Analyst forecast on CH:AG8
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
CHF150.12
Buy
―
Reiterated
08/30/26
Stifel Nicolaus Reaffirms Their Buy Rating on Agilent (A)
TD Cowen Analyst forecast on CH:AG8
Daniel Brennan
TD Cowen
TD Cowen
CHF129.27→CHF150.12
Buy
―
Assigned
08/27/26
Agilent Price Target Raised to $180 as Broad-Based Outperformance Drives Attractive Risk-Reward, Says Brennan
Piper Sandler Analyst forecast on CH:AG8
David Westenberg
Piper Sandler
Piper Sandler
CHF125.1
Hold
―
Reiterated
08/27/26
Piper Sandler Sticks to Its Hold Rating for Agilent (A)
Barclays Analyst forecast on CH:AG8
Luke Sergott
Barclays
Barclays
CHF125.1→CHF145.95
Buy
―
Reiterated
08/27/26
Agilent price target raised to $175 from $150 at BarclaysAgilent price target raised to $175 from $150 at Barclays
J.P. Morgan Analyst forecast on CH:AG8
Casey Woodring
J.P. Morgan
J.P. Morgan
CHF150.12→CHF158.46
Buy
―
Reiterated
08/27/26
Agilent price target raised to $190 from $180 at JPMorganAgilent price target raised to $190 from $180 at JPMorgan
Evercore ISI Analyst forecast on CH:AG8
Vijay Kumar
Evercore ISI
Evercore ISI
CHF123.43→CHF143.45
Buy
―
Reiterated
08/27/26
Agilent price target raised to $172 from $148 at Evercore ISIAgilent price target raised to $172 from $148 at Evercore ISI
Citi Analyst forecast on CH:AG8
Patrick B Donnelly
Citi
Citi
CHF154.29→CHF158.46
Buy
―
Reiterated
08/27/26
Agilent price target raised to $190 from $185 at CitiAgilent price target raised to $190 from $185 at Citi
RBC Capital Analyst forecast on CH:AG8
Dan Leonard
RBC Capital
RBC Capital
CHF129.27→CHF154.29
Buy
―
Reiterated
08/26/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
HSBC Analyst forecast on CH:AG8
Sidharth Sahoo
HSBC
HSBC
CHF150.12→CHF137.61
Buy
―
Reiterated
06/03/26
Agilent price target lowered to $165 from $180 at HSBCAgilent price target lowered to $165 from $180 at HSBC
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OMCLOmnicell
KNSAKiniksa Pharmaceuticals
ACHVAchieve Life Sciences
AHCOAdaptHealth
ZVRAZevra Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilent

3 Months
Dan LeonardRBC Capital
Success Rate
19/28 ratings generated profit
68%
Average Return
+5.51%
Copying Dan Leonard's trades and holding each position for 3 Months would result in 67.86% of your transactions generating a profit, with an average return of +5.51% per trade.
1 Year
Dan LeonardRBC Capital
Success Rate
23/28 ratings generated profit
82%
Average Return
+25.40%
Copying Dan Leonard's trades and holding each position for 1 Year would result in 82.14% of your transactions generating a profit, with an average return of +25.40% per trade.
2 Years
Patrick B DonnellyCiti
Success Rate
18/21 ratings generated profit
86%
Average Return
+23.76%
Copying Patrick B Donnelly's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +23.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AG8 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
2
2
1
0
0
Buy
15
15
20
21
19
Hold
2
3
4
7
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
20
25
28
25
In the current month, AG8 has received 19 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. AG8 average Analyst price target in the past 3 months is 148.21.
Each month's total comprises the sum of three months' worth of ratings.

AG8 Financial Forecast

AG8 Earnings Forecast

Next quarter’s earnings estimate for AG8 is CHF1.44 with a range of CHF1.43 to CHF1.47. The previous quarter’s EPS was CHF1.35. AG8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AG8 has Performed in-line its overall industry.
Next quarter’s earnings estimate for AG8 is CHF1.44 with a range of CHF1.43 to CHF1.47. The previous quarter’s EPS was CHF1.35. AG8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year AG8 has Performed in-line its overall industry.

AG8 Sales Forecast

Next quarter’s sales forecast for AG8 is CHF1.66B with a range of CHF1.65B to CHF1.67B. The previous quarter’s sales results were CHF1.57B. AG8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AG8 has Performed in-line its overall industry.
Next quarter’s sales forecast for AG8 is CHF1.66B with a range of CHF1.65B to CHF1.67B. The previous quarter’s sales results were CHF1.57B. AG8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year AG8 has Performed in-line its overall industry.

AG8 Stock Forecast FAQ

What is CH:AG8’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilent’s 12-month average price target is 148.21.
    What is CH:AG8’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:AG8, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Agilent a Buy, Sell or Hold?
        Agilent has a consensus rating of Strong Buy, which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.
          What is Agilent’s share price target?
          The average share price target for Agilent is 148.21. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF158.46 ,and the lowest forecast is CHF125.10. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Agilent?
            Agilent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
              How can I buy shares of Agilent?
              To buy shares of CH:AG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.